FTC Faces Pressure to Block Novo Nordisk-Catalent Merger Over Antitrust Fears

United States Senator Elizabeth Warren wrote a letter to the Federal Trade Commission’s chair, Lina Khan, urging to investigate Novo Nordisk A/S (NYSE:NVO) proposed $16.5 billion acquisition of contract development and manufacturing organization Catalent Inc (NYSE:CTLT) thoroughly, amid growing concerns about potential antitrust violations.

Critics argue that this merger could increase Novo Nordisk’s control over producing vital GLP-1 receptor agonists, drugs used to treat diabetes and obesity. This could potentially drive up prices and limit competition.

Also Read: Novo Nordisk/AstraZeneca’s Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses.

Novo Nordisk already has a dominant 55% share of the booming GLP-1 market due to the success of its blockbuster drugs, Ozempic and Wegovy.

Catalent plays a ...